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(Antigen threshold) ultimately rests on analysis of mathematical models. However, as the models have many interacting processes 108 -minimally innate immunity, adaptive immunity and intrinsic growth differences between vaccine versus inferiority. Yet even if vaccine selective 'neutrality' turns out to be fleeting, merely a mistaken impression 119 from short-term observations, we will find that the phenomenon of short-term stability mirrors a solution to 120 minimize vaccine evolution within the host. but it is widely accepted that the roles differ among infections by different viruses and that each mechanism 146 is potentially important for some viruses.
147
Innate immunity There are two broad arms of immunity for suppressing vaccine growth within the host, the 
Adaptive immunity.
165
Adaptive immunity can be induced by the wild-type vector and the vaccine virus. Adaptive immune responses 166 specific to antigens expressed by the wild-type vector will presumably affect the vaccine and revertant equally 167 -because the vaccine encodes a complete vector genome, and the revertant is also a complete vector. As with 168 the preceding pair of mechanisms, adaptive immunity common to both revertant and vaccine will operate so 169 that revertant abundance will depress vaccine. Adaptive immunity to the vaccine antigen will be considered 170 shortly. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/545087 doi: bioRxiv preprint one mechanism may take precedence over the others, simply because it is activated earlier or enforces a lower 173 limit on viral density than the others. However, there are different stages or degrees of vaccine suppression, 174 so an early mechanism may act to control the infection without clearing it, and another mechanism may 175 act later to clear. Because of the delay in developing an adaptive response, viral suppression by adaptive 176 immunity typically occurs later than effects of innate immunity or resource limitation and so might seem 177 to be unimportant in vaccine evolution. Yet adaptive immunity may be important in clearing the vaccine 178 following control by other mechanisms, in which case it could have an important role in vaccine evolution. The preceding paragraphs omitted adaptive immunity to the antigen. By its very nature, adaptive immunity 182 suppresses vaccine growth. But adaptive immunity to the antigen is specific to the vaccine and is thus 183 another reason -besides intrinsic fitness effects -that the vaccine may have lower fitness than revertant.
184
The evolutionary consequences should be the same for both types of inferiority, reducing the long term 185 generation of antigen levels. But the interesting twist is that adaptive immunity to the antigen might feed 186 back negatively on itself to limit its own growth -immunity against a virus is intrinsically inhibitory, so 187 adaptive immunity against the vaccine will limit vaccine growth and thus limit antigen build-up that would 188 fuel further immunity. One question is whether this self-inhibition is worsened with vaccine evolution.
189
The effect is biologically complicated because adaptive immunity to the antigen does not necessarily translate The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/545087 doi: bioRxiv preprint
We now employ quantitative models to evaluate the intuitive ideas presented above. Given the high 
207
The models assist us by forcing us to specify assumptions for how the viruses and immunity interact, and 208 by allowing us to rigorously explore outcomes in different scenarios. However, there is uncertainty in the 209 model structure, many parameter values are unknown, and different viruses will behave somewhat differently.
210
Consequently, we focus on broad generalities that arise from many simulations and illustrate these for a 211 few specific cases, reserving the supplement for further details. The presentation below briefly discusses 212 the individual dynamics of individual trials for illustration but then moves to plots that reveal differences 213 in outcomes as the key parameters are changed. The model used here incorporates the structure of earlier 214 models used to describe immune responses [33] [34] [35] ; parameter values used here were chosen as described in 215 some of these earlier studies. 
Evolution from intrinsic fitness effects can matter
217
In the trials used for illustration, we allow innate immunity to control the infection and adaptive immunity The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/545087 doi: bioRxiv preprint The dynamics of virus and immunity are shown in the absence of revertant (i.e. no evolution). (Right) The revertant is included, but at two different levels. The solid lines correspond to little evolution: the vaccine has a small cost (intrinsic cost =1%, initial level of W is 0.1 that of initial vaccine, and the mutation rate is 10 − 6 per day). The dotted lines correspond to major evolution: the vaccine has a 20% intrinsic cost, the mutation rate is 10 −3 , and the initial level of the revertant is 10 fold that of the vaccine.
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The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/545087 doi: bioRxiv preprint the mutation rate, the fitness of revertant (c) and the initial revertant abundance. The effect of evolution is 245 We focus on infections of short duration. Factors that limit the duration of infection include resource immunity by allowing revertant to grow and interfere with vaccine. This section considers whether these 252 arguments are supported by the model.
Vaccine evolution driven by adaptive immunity
253
Any real vaccine that elicits immunity against the antigen may also experience an intrinsic fitness cost.
254
The effect of immunity on evolution would then be confounded with the effect of intrinsic fitness effects on 255 evolution, making it difficult to isolate one from the other. The models do not face this problem, however.
256
They can be parameterized so that the only possible selection against the vaccine comes from immunity (by The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/545087 doi: bioRxiv preprint from trials that lack revertant and then compare those results with trials that include revertant.
260
There are several background points to note about the model structure. First, adaptive immunity specific 261 to vaccine (X) develops at a rate proportional to the vaccine abundance (V ) and parameters s and φ X .
262
In contrast the impairment of vaccine growth depends on the level of immunity (X) and the parameter 263 (k X ). Thus, immunity can develop even when there is little or no impairment, i.e., when k X → 0. Second, Trials were run that contrasted revertant absence versus revertant introduced at 75% of the inoculum -no 270 evolution versus evolution, respectively (Fig. 5) . Absence of the revertant is the baseline against which the 271 effect of evolution can be compared. The horizontal axis varies k X , the parameter for impairment specific to than vector -revertant is interfering less.
289
In sum, therefore, immunity to the vaccine (X) is reduced by itself and by evolution (presence of revertant).
290
The self-limiting effect of anti-vaccine immunity depends heavily on the impairment parameter. The two 291 effects do not interact to make the problem worse than from their separate effects. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/545087 doi: bioRxiv preprint is high). Second, the vaccine should elicit a large response to this antigen. This requires that the antigen 300 rapidly elicits immunity (i.e. has low φ X , and in terms of immunology it should be an immunogenic antigen), 301 and also requires a high vaccine viral load to generate a large response. Engineering this requires tackling 302 a trade-off between avoiding vaccine clearance (i.e. having a low k X ) but allowing for rapid clearance of 303 the pathogen (having a high k P ). Vaccines designed to express the antigen in a form that is different from 304 that in the pathogen might help solve this problem. Thus, to elicit immunity to influenza, one might design 305 secreted forms of the hemagglutinin or neuraminidase proteins. A recombinant hemagglutinin protein that is 306 secreted rather than on the virion surface would prevent the antibody response to this protein from clearing 307 the recombinant vector vaccine (have low k X ) without compromising the clearance of the influenza virus 308 pathogen which has hemagglutinin on its surface (i.e. has high k P ). In this manner our model allows the 309 identification and tuning of parameters that affect vaccine efficacy, and a comprehensive search of parameter 310 space would identify ideal combinations of vaccine properties. We now turn to vaccine designs that overcome 311 problems created by evolution, our specific interest here. 
Control the inoculum
313
The results above suggest that vaccine evolution is only likely to compromise immunity to the antigen if 314 there is substantial evolution and this evolution results in more rapid clearance of the vaccine virus. In this 315 case, one possible solution takes advantage of the short-term nature of vaccine growth: control the inoculum.
316
Two ways of controlling the inoculum are to control its composition and to control its size. Evolution can 317 be reduced by purifying the inoculum -an inoculum that is entirely vaccine cannot begin to give way to 318 revertant until some are generated by mutation, hence a low (or zero) density of revertant in the inoculum 319 enhances the duration of within-host vaccine utility. If it not feasible to eliminate the revertant from the 320 inoculum, it can nevertheless be beneficial to lower the frequency of the revertant virus in the inoculum.
321
The effect of revertant frequency in the inoculum is evident in Figure 6 : the magnitude of immunity to the 322 vaccine increases by orders of magnitude as the initial frequency of the revertant is decreased.
323
Evolution can also be reduced by increasing the inoculum size. To achieve a threshold antigen level, a large 324 inoculum requires less growth than a small one. Less growth means less evolution -in the extreme, a large The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/545087 doi: bioRxiv preprint appreciably increases the magnitude of immunity; a much reduced benefit is seen when revertant frequency is Composition of the vaccine has the larger effect for these parameters, as indicated by the contours being more horizontal than vertical. An intrinsic fitness cost of c = 0.1 was set for these trials. Smaller c values would lead to higher vaccine and immunity levels across the graphs.
Whether and how well controlling the inoculum will work in practice will depend on details. Solutions may 333 be quantitative rather than absolute. Intuition is useful for guidance but needs to be confirmed by formal We developed and analyzed models to explore ways in which vaccine evolution could lead to a reduction in Our results revealed that that for a broad parameter regime, within-host evolution is unlikely to cause 360 a significant loss of vaccine efficacy (i.e. reduction in the level of immunity to the inserted transgene).
361
Furthermore, undesirable consequences of vaccine evolution may often be easily remedied by ensuring the 362 frequency of the revertant virus in the inoculum is low and by increasing the size of the inoculum. We 363 also suggest that further gains in vaccine efficacy can be achieved by appropriate engineering of the vaccine 364 antigen, allowing it to elicit immunity that clears the pathogen but not the virus vaccine, although such 365 engineering may not be easy.
366
One major outcome of our analysis was that intuition about vaccine evolution was not easily translated into
intuition about immunity. Indeed, even intuition about evolution often failed because that intuition was based 368 on vaccine versus revertant fitness, but the vaccine growth phase was short enough that differential fitness 369 had little effect on evolution. Even more fundamentally, intuition sometimes failed because the development 370 of immunity to vaccine could be unaffected by the revertant. Thus, our intuition suggested that vaccine 371 inferiority could stem from both an intrinsic fitness disadvantage and a disadvantage due to adaptive immunity 372 to the transgene/antigen. Both effects were found to impair the development of immunity to vaccine, but not 373 necessarily for the reasons suggested by our intuition.
374
Measuring the intrinsic fitness effect of the transgene is likely to be an important step in vaccine design. For 375 assessing vaccine evolution, the relevant biological realm is within the host. Nonetheless, in vitro growth 376 environments may reveal much about a vaccine's intrinsic propensity to evolve loss of antigen expression.
377
There are various ways intrinsic fitness effects and their evolutionary consequences might be studied. Vaccine 
Model formulation
427
Variables
428
The following table defines the variables used in these equations. 
Equations
434
Resources start with a fixed amount and are depleted by vaccine and revertant growth, without replenishment:
The vaccine virus grows on resource R at rate r, depleted by mutation, death, and all 3 types of immunity:
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Adaptive immunity specific to vaccine grows according to its present value and a discounted value of the 438 current vaccine density:
Adaptive immunity common to vaccine and revertant grows according to its present value and a discounted 440 value of the current vaccine plus revertant densities:
Innate immunity, also common to vaccine and revertant, grows according to current levels of vaccine and 442 revertant, with diminishing growth as a limit is approached. Innate immunity also decays:
These models follow the usual assumptions of SIR models, except that susceptible hosts (host cells in our case) 444 are modeled as Resource. As is typical in these models, variables for 'free' virus are omitted, an assumption 445 based on the quasi-steady state approximation (Perelson 2002 48. Gallagher ME, Brooke CB, Ke R, Koelle K. Causes and consequences of spatial within-host viral spread. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/545087 doi: bioRxiv preprint
